Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Business
INVESTOR'S BUSINESS DAILY and GLENN LARKIN

Axsome Therapeutics Stock Meets 80-Plus RS Rating Benchmark

Axsome Therapeutics saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 71 to 84.

When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

This proprietary rating tracks technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.

Over 100 years of market history reveals that the best-performing stocks tend to have an RS Rating north of 80 as they launch their biggest price moves.

Looking For The Best Stocks To Buy And Watch? Start Here

Axsome Therapeutics stock has climbed steadily for 6 straight days, but not yet offering a good entry point. Look for the stock to offer a new chance to get in by forming a proper pattern or perhaps some consolidation.

In terms of fundamentals, the company has posted rising EPS growth over the last two quarters. Top line growth has been a different story, coming in at 0% in the most recent report.

Axsome Therapeutics holds the No. 111 rank among its peers in the Medical-Biomed/Biotech industry group. Vertex Pharmaceuticals and Amphastar Pharmaceutcls are also among the group's highest-rated stocks.

 

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.